|
Human Genome Sciences, Inc.
|
14200 Shady Grove Rd
Rockville, MD 20850
United States |
| Tel: |
1/301 309-8504 |
| URL: |
http://www.hgsi.com |
|
 |
| Primary Symbols & Exchanges: |
| HGSI - NASDAQ |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activities are to develop, manufacture and market protein and antibody drugs. The products of the Group are clinical development for chronic hepatitis C, LymphoStat-B(R) for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. The Clinical development include drugs to treat diseases like cancer, rheumatoid arthritis, lupus, hepatitis C, anthrax disease and HIV. It also has a portfolio of novel drugs in earlier stages of development, led by our TRAIL receptor antibodies in mid-stage development for cancer and including substantial financial rights to three novel drugs in the GlaxoSmithKline (GSK) clinical pipeline. It is developing Syncria as a treatment for type 2 diabetes mellitus. Syncria is generated from the genetic fusion of human albumin and GLP-1. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Human Genome Sciences, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
